Literature DB >> 16115144

The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera.

Holger Cario, Philipp S Goerttler, Cordula Steimle, Ross L Levine, Heike L Pahl.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16115144     DOI： 10.1111/j.1365-2141.2005.05683.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  19 in total

1.  AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2.

Authors:  Wei Wang; Sven Schwemmers; Elizabeth O Hexner; Heike L Pahl
Journal:  Blood       Date:  2010-03-25       Impact factor: 22.113

2.  Hereditary myeloproliferative disorders.

Authors:  Radek C Skoda
Journal:  Haematologica       Date:  2010-01       Impact factor: 9.941

3.  JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling.

Authors:  Sven Schwemmers; Britta Will; Cornelius F Waller; Khadija Abdulkarim; Peter Johansson; Björn Andreasson; Heike L Pahl
Journal:  Exp Hematol       Date:  2007-08-30       Impact factor: 3.084

4.  Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.

Authors:  Ola Landgren; Lynn R Goldin; Sigurdur Y Kristinsson; Elin A Helgadottir; Jan Samuelsson; Magnus Björkholm
Journal:  Blood       Date:  2008-05-01       Impact factor: 22.113

5.  Gene and microRNA analysis of neutrophils from patients with polycythemia vera and essential thrombocytosis: down-regulation of micro RNA-1 and -133a.

Authors:  Stefanie Slezak; Ping Jin; Lorraine Caruccio; Jiaqiang Ren; Michael Bennett; Nausheen Zia; Sharon Adams; Ena Wang; Joao Ascensao; Geraldine Schechter; David Stroncek
Journal:  J Transl Med       Date:  2009-06-04       Impact factor: 5.531

6.  JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms.

Authors:  Amy V Jones; Andrew Chase; Richard T Silver; David Oscier; Katerina Zoi; Y Lynn Wang; Holger Cario; Heike L Pahl; Andrew Collins; Andreas Reiter; Francis Grand; Nicholas C P Cross
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

7.  A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.

Authors:  Outi Kilpivaara; Semanti Mukherjee; Alison M Schram; Martha Wadleigh; Ann Mullally; Benjamin L Ebert; Adam Bass; Sachie Marubayashi; Adriana Heguy; Guillermo Garcia-Manero; Hagop Kantarjian; Kenneth Offit; Richard M Stone; D Gary Gilliland; Robert J Klein; Ross L Levine
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

8.  Transcription factor nuclear factor erythroid-2 mediates expression of the cytokine interleukin 8, a known predictor of inferior outcome in patients with myeloproliferative neoplasms.

Authors:  Julius Wehrle; Thalia S Seeger; Sven Schwemmers; Dietmar Pfeifer; Alla Bulashevska; Heike L Pahl
Journal:  Haematologica       Date:  2013-02-26       Impact factor: 9.941

9.  Elevated nuclear factor erythroid-2 levels promote epo-independent erythroid maturation and recapitulate the hematopoietic stem cell and common myeloid progenitor expansion observed in polycythemia vera patients.

Authors:  Ruzhica Bogeska; Heike L Pahl
Journal:  Stem Cells Transl Med       Date:  2013-01-22       Impact factor: 6.940

10.  A progenitor cell origin of myeloid malignancies.

Authors:  Hiroshi Haeno; Ross L Levine; D Gary Gilliland; Franziska Michor
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-21       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.